M2 Macrophage Classification of Colorectal Cancer Reveals Intrinsic Connections with Metabolism Reprogramming and Clinical Characteristics
Fengxing Huang,Youwei Wang,Yu Shao,Runan Zhang,Mengting Li,Lan Liu,Qiu Zhao
DOI: https://doi.org/10.2147/pgpm.s458798
2024-07-12
Pharmacogenomics and Personalized Medicine
Abstract:Fengxing Huang, 1, 2, &ast Youwei Wang, 1, 2, &ast Yu Shao, 1, 2, &ast Runan Zhang, 1, 2 Mengting Li, 1, 2 Lan Liu, 1, 2, &ast Qiu Zhao 1, 2, &ast 1 Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, People's Republic of China; 2 Hubei Clinical Center and Key Laboratory of Intestinal and Colorectal Diseases, Wuhan, 430071, People's Republic of China &astThese authors contributed equally to this work Correspondence: Lan Liu; Qiu Zhao, Email ; Introduction: Immune cell interactions and metabolic changes are crucial in determining the tumor microenvironment and affecting various clinical outcomes. However, the clinical significance of metabolism evolution of immune cell evolution in colorectal cancer (CRC) remains unexplored. Methods: Single-cell RNA sequencing (scRNA-seq) and bulk RNA sequencing data were acquired from TCGA and GEO datasets. For the analysis of macrophage differentiation trajectories, we employed the R packages Seurat and Monocle. Consensus clustering was further applied to identify the molecular classification. Immunohistochemical results from AOM and AOM/DSS models were used to validate macrophage expression. Subsequently, GSEA, ESTIMATE scores, prognosis, clinical characteristics, mutational burden, immune cell infiltration, and the variance in gene expression among different clusters were compared. We constructed a prognostic model and nomograms based on metabolic gene signatures identified through the MEGENA framework. Results: We found two heterogeneous groups of M2 macrophages with various clinical outcomes through the evolutionary process. The prognosis of Cluster 2 was poorer. Further investigation showed that Cluster 2 constituted a metabolically active group while Cluster 1 was comparatively metabolically inert. Metabolic variations in M2 macrophages during tumor development are related to tumor prognosis. Additionally, Cluster 2 showed the most pronounced genomic instability and had highly elevated metabolic pathways, notably those associated with the ECM. We identified eight metabolic genes (PRELP, NOTCH3, CNOT6, ASRGL1, SRSF1, PSMD4, RPL31, and CNOT7) to build a predictive model validated in CRC datasets. Then, a nomogram based on the M2 risk score improved predictive performance. Furthermore, our study demonstrated that immune checkpoint inhibitor therapy may benefit patients with low-risk. Discussion: Our research reveals underlying relationships between metabolic phenotypes and immunological profiles and suggests a unique M2 classification technique for CRC. The identified gene signatures may be key factors linking immunity and tumor metabolism, warranting further investigations. Keywords: CRC, macrophages, metabolic classification, tumor immunity, prognosis model Graphical In recent decades, colorectal cancer (CRC) has become a primary consideration of cancer-related incidence and mortality around the world. 1 The tumor microenvironment (TME) and immune cell interactions play crucial roles in CRC progression and serve as prognostic biomarkers. 2 The role of various immune cells in tumor progression has been extensively studied. Immunotherapy has shown a practical therapeutic approach in comprehensive cancer management, showing promising results in multiple types of malignancies. 3–6 Specifically, immune checkpoint inhibitors (ICI) have shown efficacy in the treatment of various types of tumors. 2 It is worth emphasizing that ICI therapy is affected by the heterogeneity of the TME, which significantly affects tumor occurrence, progression, metastasis, and treatment response, 7,8 making it a key determinant. 9 High immune cell presence and fully activated anti-tumor immune responses belonging to the "hot tumor" are associated with good therapeutic sensitivity to ICI therapy. Contrarily, a low immune infiltration corresponding to a "cold tumor" frequently denotes impaired treatment response. 9 A diverse array of immune cells play multifaceted roles in the progression of tumors. Among these, CD4+ T cells, CD8+ T cells, and macrophages have been the subject of extensive research. Specifically, tumor-associated macrophages (TAMs) have been demonstrated to possess considerable diagnostic and prognostic significance across various types of cancer, such as breast cancer, 10 pancreatic cancer, 11 hepatocellular cancer, 12 and CRC. 13 Nevertheless, there is ongoing exploration needed to understand th -Abstract Truncated-
pharmacology & pharmacy